Insmed (INSM) Reiterated at Buy by Stifel After TPIP P2b Trial Data

July 17, 2026 7:20 AM

Stifel analyst Stephen Willey reiterated a Buy rating and $200.00 price target on Insmed (NASDAQ: INSM).The analyst commented, "We believe ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found